Regeneron's bid to join the US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised after the FDA approved its Lynozyfic drug at a second attempt. Lynozyfic ...

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its approved therapy for the sleep disorder narcolepsy. Lundbeck's ...

The UK life sciences raised £1.23 billion ($1.65 billion) in venture capital investment in the first half of 2025, putting it on course to at least match the 2024 total for the full year. That's the ...

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...

Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a precursor ...

Healthcare in the UK is at an inflection point. To ensure the NHS remains fit for the future, the Government launched its 10-Year Health Plan for England last year, setting out strong ambitions around ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings. The ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

Khalil Asmar, VP of cardiometabolic health at Lilly UK & Ireland (l), and former England spin bowler Ashley Giles (r). Like ...

AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic ...

Big Tech platforms continue to roll out AI health assistants at scale, with Amazon’s new agent the latest to be integrated ...

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...